Labcorp药物开发博客
Your source for answers to the complex challenges of cell and gene therapy development. We recently sat down with Maryland Franklin, Vice President and Enterprise Head of Cell & Gene Therapy at Labcorp Drug Development, to discuss key considerations for developing cell or gene therapies in today’s quickly expanding pipeline.
On July 29, 2021, Labcorp announced it is expanding its oncology portfolio by acquiring OmniSeq, a pioneer in solid tumor profiling that harnesses next-generation sequencing technologies and aids drug development through wide-ranging pharmaceutical services. The transaction bolsters Labcorp’s growing portfolio of diagnostic tests and clinical trial opportunities for people with …
In our previous edition of the blog, we highlighted our upcoming presence at DIA. Our focus at the show this year was patient diversity, patient equity, and patient engagement. The recordings from the show are now available, so this month we will point you toward those in case you missed …
Categorizing and centralizing cross-study, cross-functional risk data As part of our Xcellerate® technology suite, we developed a risk library based on cross-functional input identifying the most common risks to our clinical studies, regardless of clinical phase. These common study risks became the foundation of the risk library available to users …
Identifying viable study sites presents a challenge in many clinical trials. Biosimilar development is especially challenging as the number of sponsors preparing to broaden access to today’s blockbuster biologics, by providing lower-cost biosimilar alternative, continues to grow. While this flood of research activity will make a significant improvement for patient …
This month in the DCT Blog, we are going to put the spotlight on several events coming up in the next few weeks.
To meet the increased demand of pharmaceutical and biotechnology companies and drive continued growth, we are pleased to announce the expansion of its bioanalytical operations in Asia-Pacific. This new laboratory in Singapore will be co-located with its Central Laboratory Services and Clinical Development & Commercialization Services.
Risk-based quality management methodologies address risk control and management during execution of a clinical trial. RBQM adoption has generated valuable benefits for project management and clinical operations, changing the way trial monitoring is done. However, data management activities are ideally suited for an RBQM approach as well. Today, we explore …
On April 15, we hosted the virtual conference, “Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery.” For study teams working to develop treatments for patients suffering from neurodegenerative diseases, the need to leverage new techniques quickly and effectively is imperative. This topic is vital, as nearly 50 million people worldwide suffer …
Sometimes success isn’t about the pieces that you have at your disposal, but rather it comes from how these pieces connect to each other, transforming a process and leading to a better outcome.
